TY  - JOUR
AU  - Galldiks, Norbert
AU  - Albert, Nathalie L.
AU  - Sommerauer, Michael
AU  - Grosu, Anca L.
AU  - Ganswindt, Ute
AU  - Law, Ian
AU  - Preusser, Matthias
AU  - Le Rhun, Emilie
AU  - Vogelbaum, Michael A.
AU  - Zadeh, Gelareh
AU  - Dhermain, Fr?d?ric
AU  - Weller, Michael
AU  - Langen, Karl-Josef
AU  - Tonn, J?rg C.
TI  - PET Imaging in Patients with Meningioma - Report of the RANO/PET Group
JO  - Neuro-Oncology
VL  - 19
IS  - 12
SN  - 1523-5866
CY  - Oxford
PB  - Oxford Univ. Press
M1  - FZJ-2017-04120
SP  - 1576–1587
PY  - 2017
AB  - Meningiomas are the most frequent nonglial primary brain tumors and represent about 30% of brain tumors. Usually, diagnosis and treatment planning are based on neuroimaging using mainly MRI or, rarely, CT. Most common treatment options are neurosurgical resection and radiotherapy (eg, radiosurgery, external fractionated radiotherapy). For follow-up after treatment, a structural imaging technique such as MRI or CT is used. However, these structural imaging modalities have limitations, particularly in terms of tumor delineation as well as diagnosis of posttherapeutic reactive changes. Molecular imaging techniques such as PET can characterize specific metabolic and cellular features which may provide clinically relevant information beyond that obtained from structural MR or CT imaging alone. Currently, the use of PET in meningioma patients is steadily increasing. In the present article, we provide recommendations for the use of PET imaging in the clinical management of meningiomas based on evidence generated from studies being validated by histology or clinical course.
LB  - PUB:(DE-HGF)16
C6  - pmid:28605532
UR  - <Go to ISI:>//WOS:000417204200010
DO  - DOI:10.1093/neuonc/nox112
UR  - https://juser.fz-juelich.de/record/834120
ER  -